Risk factors for invasive aspergillosis in acute myeloid leukemia patients prophylactically treated with posaconazole

References

• Michallet M, Ito JI. Approaches to the management of invasive fungal infections in hematologic malignancy and hematopoietic cell transplantation. J Clin Oncol 2009;27:3398–3409.
   PubMed Web of Science ®Google Scholar
• Lin SJ, Schranz J, Teutsch SM. Aspergillosis case-fatality rate: systematic review of the literature. Clin Infect Dis 2001;32:358–366.
   PubMed Web of Science ®Google Scholar
• Mahfouz T, Anaissie E. Prevention of fungal infections in the immunocompromised host. Curr Opin Investig Drugs 2003;4:974–990.
   PubMedGoogle Scholar
• Hughes WT, Armstrong D, Bodey GP, . Guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis 2002; 34: 730–7.
   PubMed Web of Science ®Google Scholar
• Maertens J, Theunissen K, Verhoef G, . Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis 2005;41:1242–1250.
   PubMed Web of Science ®Google Scholar
• De Pauw B, Walsh TJ, Donnelly JP, . Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/invasive fungal infections cooperative group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) consensus group. Clin Infect Dis 2008;46:1813–1821.
   PubMed Web of Science ®Google Scholar
• Schiller DS, Fung HB. Posaconazole: an extended-spectrum triazole antifungal agent. Clin Ther 2007;29:1862–1886.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Maertens J, Winston D, . Posaconazole vs. fluconazole or itraconazole prophylaxis in patients with neutropenia. N Engl J Med 2007;356:348–359.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Lipton JH, Vesole DH, . Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease. N Engl J Med 2007;356:409–411.
   Google Scholar
• Herbrecht, R., Letscher-Bru V, Oprea C, . Aspergillus galactomannan detection in the diagnosis of invasive aspergillosis in cancer patients. J Clin Oncol 2002;20:1898–1906.
   PubMed Web of Science ®Google Scholar
• Marr KA, Balajee SA, McLaughlin L, . Detection of galactomannan antigenemia by enzyme immunoassay for the diagnosis of invasive aspergillosis: variables that affect performance. J Infect Dis 2004;190:641–649.
   PubMed Web of Science ®Google Scholar
• Fine JP, Gray RJ. A proportional hazards model for the subdistribution of a competing risk. J Am Stat Assoc 1999;94:496–509.
   Web of Science ®Google Scholar
• Cox D. Regression models and life-tables. J R Stat Soc 1972;34:187–220.
   Google Scholar
• Cornely OA, Ullmann AJ. Numbers needed to treat with posaconazole prophylaxis to prevent invasive fungal infection and death. Clin Infect Dis 2008;46:1626–1627.
   PubMed Web of Science ®Google Scholar
• De Pauw BE, Donnelly JP. Prophylaxis and aspergillosis – has the principle been proven? New Engl J Med 2007; 356: 409.
   PubMed Web of Science ®Google Scholar
• Vehreschild JJ, Rüping MJ, Wisplinghoff H, . Clinical effectiveness of posaconazole prophylaxis in patients with acute myelogenous leukaemia (AML): a 6 year experience of the Cologne AML cohort. J Antimicrob Chemother 2010;65:1466–1471.
   PubMed Web of Science ®Google Scholar
• Cordonnier C, Ribaud P, Herbrecht R, . Société Française de Greffe de Moelle et de Thérapie Cellulaire. Prognostic factors for death due to invasive aspergillosis after hematopoietic stem cell transplantation: a 1-year retrospective study of consecutive patients at French transplantation centers. Clin Infect Dis 2006;42:955–963.
   PubMed Web of Science ®Google Scholar
• Upton A, Kirby KA, Carpenter P, . Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin Infect Dis 2007;44:531–540.
   PubMed Web of Science ®Google Scholar
• Nivoix Y, Velten M, Letscher-Bru V, . Factors associated with overall and attributable mortality in invasive aspergillosis. Clin Infect Dis 2008;47:1176–1184.
   PubMed Web of Science ®Google Scholar
• Parody R, Martino R, Sanchez F, . Predicting survival in adults with invasive aspergillosis during therapy for hematological malignancies or after hematopoietic stem cell transplantation: single-center analysis and validation of the Seattle, French, and Strasbourg prognostic indexes. Am J Hematol 2009;84:571–578.
   PubMed Web of Science ®Google Scholar
• Humphreys H. Positive-pressure isolation and the prevention of invasive aspergillosis. what is the evidence? J Hosp Infect 2004;56:93–100.
   PubMed Web of Science ®Google Scholar
• Hajjeh RA, Warnock DW. Counterpoint: invasive aspergillosis and the environment-rethinking our approach to prevention. Clin Infect Dis 2001 Nov 1; 33(9): 1549–52.
   Google Scholar